Ken Griffin Avidity Biosciences, Inc. Transaction History

Citadel Advisors LLC

$505 Billion
Q3 2024

A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Avidity Biosciences, Inc. stock. As of the latest transaction made, Citadel Advisors LLC holds 41,400 shares of RNA stock, worth $1.81 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

41,400

Previous 12,600 228.57%

Holding current value

$1.81 Million

Previous $514,000 269.84%

% of portfolio

0.0%

Previous 0.0%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	BUY	$22.73 - $40.85 $1.31 Million - $2.35 Million	57,644 Added 55.89%	160,777 $6.57 Million
Q1 2024 May 15, 2024	SELL	$9.16 - $25.52 $3.58 Million - $9.97 Million	-390,529 Reduced 79.11%	103,133 $2.63 Million
Q4 2023 Feb 14, 2024	BUY	$4.87 - $9.37 $1.28 Million - $2.47 Million	263,314 Added 114.31%	493,662 $4.47 Million
Q3 2023 Nov 14, 2023	SELL	$6.3 - $11.35 $774,263 - $1.39 Million	-122,899 Reduced 34.79%	230,348 $1.47 Million
Q2 2023 Aug 14, 2023	BUY	$10.62 - $17.34 $2.64 Million - $4.3 Million	248,225 Added 236.36%	353,247 $3.92 Million
Q1 2023 May 15, 2023	BUY	$15.35 - $25.65 $1.5 Million - $2.5 Million	97,398 Added 1277.52%	105,022 $1.61 Million
Q4 2022 Feb 14, 2023	SELL	$10.06 - $22.66 $490,696 - $1.11 Million	-48,777 Reduced 86.48%	7,624 $169,000
Q3 2022 Nov 14, 2022	BUY	$15.46 - $23.43 $268,045 - $406,229	17,338 Added 44.38%	56,401 $921,000
Q2 2022 Aug 15, 2022	BUY	$11.18 - $20.5 $223,208 - $409,282	19,965 Added 104.54%	39,063 $568,000
Q1 2022 May 16, 2022	BUY	$14.2 - $23.78 $271,191 - $454,150	19,098 New	19,098 $353,000
Q3 2020 Nov 16, 2020	SELL	$23.35 - $35.94 $6.38 Million - $9.82 Million	-273,220 Closed	0 $0
Q2 2020 Aug 14, 2020	BUY	$26.62 - $31.5 $7.27 Million - $8.61 Million	273,220 New	273,220 $7.72 Million

Others Institutions Holding RNA

# of Institutions

256

Shares Held

107M

Call Options Held

224K

Put Options Held

161K

View Full List

About Avidity Biosciences, Inc.

Ticker RNA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 52,127,000
Market Cap $2.28B
Description
Avidity Biosciences, Inc., a biopharmaceutical company, engages in the development of oligonucleotide-based therapies. It develops antibody oligonucleotide conjugates (AOC) that are designed to treat a range of serious diseases. The company's lead product candidate AOC 1001 is used for the treatment of myotonic dystrophy type 1, a rare monogenic...

More about RNA

Track Ken Griffin's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.

Account